Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

341
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
341
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply.

Retina (Philadelphia, Pa.)·2016
Same author

RETINAL VEIN OCCLUSIONS, FROM BASICS TO THE LATEST TREATMENT.

Retina (Philadelphia, Pa.)·2015
Same author

Prospective Randomized Comparative Study of the Effect of Pupil Dilation or Miosis in Intraocular Lens Pupillary Capture After Combined Phacoemulsification and Vitrectomy With Intraocular Tamponade.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2015
Same author

Management of Choroidal Neovascularization Secondary to Pathological Myopia: The Era of Changes.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2015
Same author

Genes in the high-density lipoprotein metabolic pathway in age-related macular degeneration and polypoidal choroidal vasculopathy.

Ophthalmology·2014
Same author

Prevalence and risk factors of posterior vitreous detachment in a Chinese adult population: the Handan eye study.

BMC ophthalmology·2013
Same journal

Benchmarking and fine-tuning vision-language models on a visual question answering dataset for myopic maculopathy.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026
Same journal

Does lens opacity matter? The effect of cataract on deep learning based cardiovascular disease risk scores from fundus photos.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026
Same journal

Corrigendum to "Oculomics and AI: The eye as a biomarker for health span" [Asia-Pac J Ophthalmol 15 (1) (2026) 100282].

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026
Same journal

Visual preservation and surgical outcomes of phacogoniotomy in end-stage glaucoma: A multicenter study.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026
Same journal

Association of asymmetrical normal tension glaucoma, obstructive sleep apnoea and side sleeping.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026
Same journal

Mechanism of myopic axial elongation related to Bruch´s membrane.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026
See all related articles

Related Experiment Video

Updated: Apr 8, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.4K

Review of Intermediate Uveitis.

Frank H P Lai1, David T L Liu, Dennis S C Lam

  • 1From the Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, The People's Republic of China.

Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.)
|June 25, 2015
PubMed
Summary
This summary is machine-generated.

This review covers medical and surgical treatments for intermediate uveitis (IU), an eye inflammation. While corticosteroids are primary, newer therapies like immunosuppressants and biologics offer evolving management options.

More Related Videos

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.3K
Intravitreous Injection for Establishing Ocular Diseases Model
05:37

Intravitreous Injection for Establishing Ocular Diseases Model

Published on: October 1, 2007

38.2K

Related Experiment Videos

Last Updated: Apr 8, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.4K
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.3K
Intravitreous Injection for Establishing Ocular Diseases Model
05:37

Intravitreous Injection for Establishing Ocular Diseases Model

Published on: October 1, 2007

38.2K

Area of Science:

  • Ophthalmology
  • Immunology

Background:

  • Intermediate uveitis (IU) is typically a benign inflammatory eye condition.
  • IU can be associated with systemic disorders, necessitating exclusion of masquerade syndromes and infections.
  • Understanding IU immunopathology has driven new therapeutic developments.

Purpose of the Study:

  • To review current evidence on medical and surgical management of intermediate uveitis (IU).
  • To highlight updated understandings of IU immunopathology and its impact on treatment.
  • To provide a comprehensive overview of evolving therapeutic strategies for IU.

Main Methods:

  • Retrospective literature review.
  • Searches conducted in PubMed and OVID databases.
  • Selection of relevant articles on intermediate uveitis management.

Main Results:

  • Corticosteroids remain the primary treatment for intermediate uveitis.
  • Immunosuppressants and biological agents represent evolving treatment options.
  • Individualized management is crucial, considering disease cause and complications.

Conclusions:

  • Management of intermediate uveitis is becoming more sophisticated with new therapies.
  • Tailoring treatment to individual patient needs is essential for optimal outcomes.
  • Continued research into IU pathogenesis will likely yield further treatment advancements.